Tamoxifen helps postirradiation recovery of lymphocyte subpopulations (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Tamoxifen helps postirradiation recovery of lymphocyte subpopulations (Meeting abstract).

CCPC-93: Second International Cancer Chemo Prevention Conference. April 28-30, 1993, Berlin, Germany, p. 102, 1993.. Unique Identifier : AIDSLINE ICDB/94696782
Lukac J; Kordic D; Kusic Z; Nuclear Medicine and Oncology Dept., University Hosp. 'Sestre; milosrdnice,' Zagreb, Croatia

Abstract: Besides its antiestrogenic activity, tamoxifen (TMX) seems to exert immunomodulatory effects, suppressing lymphocyte responsiveness to mitogens, potentiating natural killer (NK) activity and increasing the number of circulating NK cells as well. We have compared absolute numbers of CD4+ and CD8+ T lymphocytes, B lymphocytes, NK cells (CD16+) and monocytes in two groups of patients with ductal invasive carcinoma of the breast, Stage II and III, before telecobalt radiotherapy (TCT; postoperative, 40-55 Gy) and 4-12 mo later. One group (15 pts, 11 Stage II, 4 St III) received no further therapy while the other (14 pts, 10 St II, 4 St III) was treated with TMX, 20 mg/day. There was no difference between two groups in any cell count before TCT. Four to 12 mo later, the absolute number of CD4+ (median, [M]=0.375x10(9)/L, p=0.001), CD8+ (0.206, p=0.001), B (0.058, p=0.004) and CD 16+ (0.089, p=0.05) lymphocytes was significantly decreased in patients not receiving TMX, compared to their pre-TCT values (M=0.778; 0.433; 0.085, respectively) while monocyte number showed no significant difference (M=0.244 vs 0.196). There was no difference between pre- and post-TCT values in patients on TMX in any parameter tested. It seems that TMX helps postirradiation recovery of lymphocyte populations, which may contribute to patients' survival and indicate its role in chemoprevention.

Keywords: B-Lymphocytes Breast Neoplasms/*IMMUNOLOGY/RADIOTHERAPY/THERAPY Carcinoma, Infiltrating Duct/*IMMUNOLOGY/RADIOTHERAPY/THERAPY CD4-CD8 Ratio Female Human Killer Cells, Natural Leukocyte Count Monocytes T-Lymphocytes Tamoxifen/*PHARMACOLOGY/THERAPEUTIC USE ABSTRACT
940530
M9450901

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .